Chantix (Critical Review)

Paddock, C. (2008, January 21). Chantix Label Updated To Warn Of Suicide Risk. Retrieved September 12, 2010, from

Who-Catharine Paddock has a Bachelor of Science in Chemistry with Physics and a PhD in Business Administration from the Manchester Business School at the University of Manchester, UK. She has also trained as a counselor, specializing in cognitive behavioral and brief therapy. She also spent five years working with employee counseling organizations, running workshops, trauma debriefs and seeing clients in one to one therapy. Her credentials are very specific for this article.
What-The recent drug Chantix® is the first non-nicotine based smoking cessation drug to come out within the past 10 years, but the psychological side effects may not be worth it. This argument is very logical, though smoking is one of the leading causes of avoidable premature deaths, depression and thoughts of suicide may be slightly less desirable than an early death. This seems very reasonable, and the only evidence against it is stated in the article, where many of the drug trials done have shown that psychological effects were caused by patients that already exhibited some sort of psychological illness.
How-Trials using the drug vs. a placebo were mentioned, as well as the results of other patients that have already used Chantix® and information on how it affected them. Since that majority of the supporting evidence is independent of the company who actually sells the drug, it is credible and is the exact kind of evidence I would think was needed to test the argument.
When-This article was posted 21 Jan 2008 - 3:00 PDT. It is current and should stand the test of time due to its credible resources and logical arguments, but science is always growing and improving.
Where-Medical News Today has well-regarded sources such as JAMA, BMJ, Lancet, BMA, plus articles written by their own team of independent researchers, their...